28 Li Y, Chen J. Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi, 2019, 48(8): 585-589. [李媛, 陈杰. PD-L1检测在非小细胞肺癌免疫治疗标志物筛选中面临的挑战. 中华病理学杂志, 2019, 48(8): 585-589.] doi...
[2]Tsao, MING SOUND, et al. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. Aurora, CO: International Association for the Study of Lung Cancer (2017). [3]2018 ESMO handbook of immune-oncology. [4]Davis, Andrew ...
[26]Hunter, Katerina Ancevski, Mark A. Socinski, and Liza C. Villaruz. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Molecular diagnosis & therapy 22.1 (2018): 1-10. [27]Hirsch, Fred R., et al. PD-L1 immunohistochemistry assays for lu...
[5] Tsao MS, Kerr KM, Dacic S,et al. IASLC Atlas of PD-L1 Immunohistochemistry testing in lung cancer. 1st ed. Aurora: International Association for the Study of Lung Cancer, 2017. 1.早孕可做:孕5周可做,检测结果早知道。 2.结果精准:全新二代测序,检测近万位点。 3.母婴安全:仅需采集孕妇...
mNSCLCmetastaticNonSmall-CellLungCancer POPLAR:ARandomizedAll-comerPhaseIIStudy MetastaticorlocallyadvancedNSCLC(2L/3L) Diseaseprogressiononapriorplatinumtherapy N287 Atezolizumab 1200mgIVq3w §StratificationFactorsRuntillossofclinicalbenefit •PD-L1ICexpression(0vs.1vs.2vs.3)a ...
PMD14 - PDL1 TESTING PATTERNS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER IN ISRAEL - AN ANALYSIS OF REAL WORLD DATAdoi:10.1016/j.jval.2018.09.1463Apter, L.Sharman Moser, S.Chandwani, S.Shalev, V.Chodick, G.Siegelmann-Danieli, N....
Prevalence of EGFR and PDL1 testing in a population-based lung cancer surgical resection cohort from 2018-2022. e20585#Background:Most long-term survivors of lung cancer had surgery for early stage disease, but long-term survival rates are about 50%. In 2020 and 2021... M Smeltzer,O Aki...
Already in Phase III testing for melanoma and non-small-cell lung cancer, the neoantigen therapy mRNA-4157 has now started three new mid- to late-stage trials in cutaneous squamous cell carcinoma, high-risk muscle invasive bladder cancer and renal cell carcinoma, all in the adjuvant setting....
Next, we investigated whether the anti-metastatic activity was related to limiting the spread or to actively eliminating disseminated cells. IHC analysis of lung sections suggested the latter since TAIIcells homed to cancerous tissue in the lung (Fig.5a). To examine this, we evaluated the effic...
[2]Tsao, MING SOUND, et al. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. Aurora, CO: International Association for the Study of Lung Cancer (2017). [3]2018 ESMO handbook of immune-oncology. [4]Davis, Andrew A., and Vaibhav G. Patel. The role of PD-L1 expression...